DESTINY-Breast09
Showed Enhertu plus pertuzumab beats the decade-old first-line standard for HER2-positive metastatic breast cancer.
PFS 40.7 vs 26.9 months (HR 0.56). Replaces CLEOPATRA-era THP as first-line.
- Median 40.7 vs 26.9 months with Trastuzumab deruxtecan + pertuzumab compared with Taxane + trastuzumab + pertuzumab; about 13.8 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 44 percent lower chance of the event at any given time (hazard ratio 0.56, likely range 0.44 to 0.71).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- 85.1 vs 78.6 out of 100 had their tumour shrink with Trastuzumab deruxtecan + pertuzumab compared with Taxane + trastuzumab + pertuzumab; 6.5 more per 100.
- Roughly one extra person helped for every 15 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- Numbers are not recorded here for this endpoint. Trastuzumab deruxtecan + pertuzumab: Immature at the interim analysis; early trend favoured T-DXd + pertuzumab.; Taxane + trastuzumab + pertuzumab.
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- Immature at the interim analysis; early trend favoured T-DXd + pertuzumab.
- These results apply to the people the trial enrolled: First-line HER2+ metastatic breast cancer: T-DXd + pertuzumab vs THP. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (HER2); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
1,157 participants enrolled.
Immature at the interim analysis; early trend favoured T-DXd + pertuzumab.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (BICR), T-DXd + pertuzumab vs THPprimary | Trastuzumab deruxtecan + pertuzumab | 383 | 40.7 months | 0.56 (0.44–0.71) | <0.00001 | link |
| Taxane + trastuzumab + pertuzumab | 387 | 26.9 months | ||||
| Objective response rate | Trastuzumab deruxtecan + pertuzumab | — | 85.1% | — | — | — |
| Taxane + trastuzumab + pertuzumab | — | 78.6% | ||||
| Overall survival | Trastuzumab deruxtecan + pertuzumab | — | Immature at the interim analysis; early trend favoured T-DXd + pertuzumab. | — | — | — |
| Taxane + trastuzumab + pertuzumab | — | — |
Pages like this
not linked directly; found by shared links- TrialDESTINY-Breast03
Shares Javier Cortés, Vall d'Hebron University Hospital / VHIO, Trastuzumab deruxtecan, HER2-positive breast cancer.
- TrialCLEOPATRA
Shares Javier Cortés, Pertuzumab, HER2-positive breast cancer.
- TrialPHERGain
Shares Javier Cortés, Pertuzumab, HER2-positive breast cancer.
- TrialHER2CLIMB-05
Shares Pertuzumab, HER2-positive breast cancer.
- TrialAPT (adjuvant paclitaxel-trastuzumab)
- IdeaCan T-DXd alone cure early HER2-positive disease?
Shares Pertuzumab, Trastuzumab deruxtecan, HER2-positive breast cancer.
- PersonJoaquín Arribas
Shares Vall d'Hebron University Hospital / VHIO, HER2-positive breast cancer.
- ProductTrastuzumab duocarmazine